Glycan-modified anti-CD4 antibodies for HIV prevention and therapy

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9790276
SERIAL NO

14132667

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein are glycan-modified anti-CD4 monoclonal antibodies with N-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for HIV prevention and therapy are also disclosed.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE ROCKEFELLER UNIVERSITY1230 YORK AVENUE NEW YORK NY 10065

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ho, David D Chappaqua, US 30 266
Song, Ruijiang Rego Park, US 3 61

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 17, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 17, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00